Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Stem Cell Res. 2013 Feb 5;10(3):428–441. doi: 10.1016/j.scr.2013.01.010

Figure 3. Role of lysosomal proteases in ETO PCD.

Figure 3

A. ESCs were treated with ETO or left nontreated and coincubated with zFA to inhibit lysosomal proteases B, L, S, and H, PD150606 to inhibit calpains 1 and 2, or a cathepsin G inhibitor and subjected to flow cytometry to measure loss of plasma membrane integrity. A minimum of 6 experiments are displayed. Error bars represent the SEM. B. ESCs were treated with zFF and cotreated with ETO as indicated. Flow cytometry measuring violet cell stain is displayed. C. RT-PCR of murine cathepsins. RNA was isolated from nontreated MEFs, ESCs, as well as ESCs treated with ETO and harvested at the 4/24 and 4/48 time points. Complimentary DNA was generated and PCR was performed using primers designed against murine cathepsins. Gapdh served as a loading control. D. ESCs were treated as indicated and whole cell extracts were used for western blots. Levels of inactive (pro) and active cathepsins are displayed. Actin served as a loading control. *p<0.05#p<0.01.